Rakuten Medical Enrolls First Patient in the U.S. Clinical Trial for its Lead Product, ASP-1929 in Combination with Anti-PD1 Therapy, for Head and Neck Cancer or Cutaneous Squamous Cell Carcinoma
SAN MATEO, Calif., Dec. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Rakuten Medical, Inc. (Rakuten Medical) today announced that their Phase 1b/2 clinical trial, an Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 ... Biopharmaceuticals, Oncology Rakuten Medical, photoimmunotherapy, Illuminox (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 23, 2020 Category: Pharmaceuticals Source Type: news
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Company to Host Investor Conference Call Today at 8:30AM EST
PRINCETON, N.J., Dec. 22, 2020 -- (Healthcare Sales & Marketing Network) -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on develo... Biopharmaceuticals, Oncology Soligenix, dusquetide, oral mucositis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 22, 2020 Category: Pharmaceuticals Source Type: news
Study: COVID-19 rates low among those who have head, neck cancer surgery
Three percent of patients undergoing surgery for head and neck cancer in 26 countries worldwide last spring tested positive for COVID-19 within 30 days of their procedures, according to a study in the journal Cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - December 21, 2020 Category: Consumer Health News Source Type: news
Study reveals low risk of COVID-19 infection among patients undergoing head and neck cancer surgery
(Wiley) A recent international observational study provides important data on the safety of head and neck cancer surgery during the COVID-19 pandemic. The findings are published early online in CANCER, a peer-reviewed journal of the American Cancer Society. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 21, 2020 Category: International Medicine & Public Health Source Type: news
NIDCR's Winter 2020 E-Newsletter
Having trouble viewing this email? View it as a Web page.
NIDCR's Winter 2020 E-Newsletter
In this issue:
NIDCR News
Funding Opportunities
NIH/HHS News
Funding Notices
Science Advances
Subscribe to NICDR News
Grantee News
NIDCR News
NIDCR Welcomes New Director Rena D’Souza
Rena N. D’Souza, DDS, MS, PhD, was sworn in as the director of NIDCR by NIH Director Francis S. Collins, MD, PhD, on October 13. Prior to joining NIH, Dr. D’Souza was the assistant vice president for academic affairs and education for health sciences at the Un...
Source: NIDCR Science News - December 4, 2020 Category: Dentistry Source Type: news
NHS England Starts Pilot Trial of Blood Test for Many Cancers NHS England Starts Pilot Trial of Blood Test for Many Cancers
Patients with head and neck, pancreatic, and other hard-to-spot cancers could soon have their disease picked up early with a simple blood test if a pilot by National Health Service (NHS) England is a success.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Study: Telemedicine use disparity during COVID-19 among head and neck cancer patients
(Henry Ford Health System) Retrospective research by Henry Ford otolaryngologists found telemedicine use disparity among head and neck cancer patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 2, 2020 Category: Cancer & Oncology Source Type: news
Channeling the immune system for head and neck cancer
(University of Cincinnati) University of Cincinnati researchers have discovered new clues into why some people with head and neck cancer respond to immunotherapy, while others don't. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 24, 2020 Category: International Medicine & Public Health Source Type: news
Personalized cancer vaccine clinical trial to expand following promising early results
(University of Arizona Health Sciences) A University of Arizona Health Sciences clinical trial to study safety and effectiveness of a personalized cancer vaccine combined with immunotherapy drug Pembrolizumab will expand after promising preliminary data was presented at the Society for the Immunotherapy of Cancer's annual meeting. Researcher Julie E. Bauman, MD, MPH, reported data on the first 10 patients with head and neck cancer, seven of whom were treated at Banner - University Medicine, clinical partner for the UArizona Cancer Center. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 10, 2020 Category: International Medicine & Public Health Source Type: news
Proton Beam and Gabapentin Improve Care in Head and Neck Cancer Proton Beam and Gabapentin Improve Care in Head and Neck Cancer
Proton beam therapy and prophylactic gabapentin each offers significant quality-of-life benefits for patients with head and neck cancer, two studies indicate.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - November 6, 2020 Category: Surgery Tags: Hematology-Oncology News Source Type: news
Proton Beam, Gabapentin Improve Care in Head and Neck Cancer Proton Beam, Gabapentin Improve Care in Head and Neck Cancer
Proton beam therapy and prophylactic gabapentin each offers significant quality-of-life benefits for patients with head and neck cancer, two studies indicate.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 6, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Development of a protocol for assessment of suicide risk in patients with head and neck cancer - Anderson JM, Gibbison R, Twigg JA, Kanatas A.
Head and neck cancer (HNC) is the 7th most prevalent cancer globally, with an increasing incidence in recent years which is expected to continue. For many patients, the experience of receiving a diagnosis of HNC and subsequent treatment is disturbing and t... (Source: SafetyLit)
Source: SafetyLit - November 4, 2020 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
PFUA Intake and Head and Neck and Gastric Cancer Incidence PFUA Intake and Head and Neck and Gastric Cancer Incidence
Can dietary intake of dietary long-chain n-3 polyunsaturated fatty acid protect against head and neck or upper GI cancers?American Journal of Epidemiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 3, 2020 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news
European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news
European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news
